Determination of pyridostigmine bromide and its metabolites in biological samples

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 9, Issue 1, 2006, Pages 71-81

  Zhao, Bin ^a   Moochhala, Shabbir M ^a   Lu, Jia ^a   Tan, Donna ^a   Lai, Mui Hoon ^a  

^a DSO NATIONAL LABORATORIES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; DRUG METABOLITE; PYRIDOSTIGMINE; QUATERNARY AMMONIUM DERIVATIVE;

AQUEOUS SOLUTION; CAPILLARY ELECTROPHORESIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG DETERMINATION; DRUG ELIMINATION; DRUG ISOLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; LIQUID LIQUID EXTRACTION; MYASTHENIA GRAVIS; NONHUMAN; PH; RADIOIMMUNOASSAY; REVIEW; SEPARATION TECHNIQUE;

ANIMALS; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MYASTHENIA GRAVIS; PLASMA; PYRIDOSTIGMINE BROMIDE; REPRODUCIBILITY OF RESULTS; URINE;

EID: 33644550959     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Havel, J.; Patocka, J.; Bocaz, G. Determination of physostigmine and pyridostigmine in pharmaceutical formulations by capillary electrophoresis. J Cap. Elec. Microchip Tech. 7: 107-112. 2002.
2. Fisher D.M. Clinical pharmacology of neuromuscular blocking agents. Am J Health Syst Pharm. 56(11 Suppl 1): S4-9.1999.
3. Breyer-Pfaff, U.; Maier, U.; Brinkmann, A.M.; Schumm, F. Pyridostigmine kinetics in bealthy subjects and patients with myasthenia gravis. Clin. pharmacol. Ther. 37: 495-501. 1985.
4. Sapolsky, R.M. The stress of Gulf War Syndrome. Nature. 393: 308-309. 1998.
5. Blick, D.W.; Murphy, M.R.; Brown, G.C.; Yochmowitz, M.G.; Fanton, J.W.; Hartgraves, S.L. Acute behavioral toxicity of pyridostigmine or soman in primates. Toxicol. Appl. Pharmacol. 126: 311-318. 1994.
6. Marino, M.T.; Schuster, BG; Brueckner; R.P.; Lin, E.; Kaminskis, A.; Lasseter, K.C. Population pyridostigmine bromide for pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J. Clin. Pharmacol. 38: 227-235. 1998.
7. Gordan, J J.; Leadbeater, L., Maidment, M.P. The protection of animals against organophosphate poisoning by pre-treatment with a carbamate. Toxicol. Appl. Pharmacol. 52:71-92. 1978.
8. Song, X.; Pope, C.; Murthy, R.; Shaikh, J.; Lal, B.; Bressler, J.P. Interactive effects of paraoxon and pyridostigmine on blood-brain barrier integrity and cholinergic toxicity. Toxicol Sci. 78: 241-247. 2004.
9. Cook, J.E.; Kolka. M.A.; Wenger, C.B. Chronic pyridostigmine bromide administration: side effects among soldiers working in a desert environment. Mil. Med. 157: 250-254.1992.
10. Izraeli, S.; Avgar, D.; Almog, S.; Shochat, I.: Tochner, Z.; Tamir, A. Tbe effect of repeated doses of 30 mg pyridostigmine bromide on pilot performance in an A-4 flight simulator. Aviat. Space Fnviron. Med 61: 430-432. 1999
11. Wenger, B.; Quigley, M.D.; Kolka, M.A. Seven-day pyridostigmine administration and thermoregulation during rect and exercise in dry heat. Aviat. Space Environ. Med. 64: 905-911. 1993.
12. Aquilonius, S-M.; Hartvig, P. Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinetics. 11: 23-249. 1986.
13. Yakatan, G.J.; Tien J-Y. Quantitation of pyridostigmine in plasma using high-performance liquid chromatography. J Chromatogr. 164: 399-403. 1979.
14. Ellin, R.I.; Zvirblis, P., Wilson, M.R. Method for isolation and determination of pyridostigmine and metabolites in urine and blood. J. Chromatogr. 228: 235-244. 1982.
15. 14C labelled pyridostigmine in myasthenia gravis. Evidence for multiple metabolites. Neurology (Minneap.) 20: 634-641. 1970.
16. Barber, H.E.; Bourne, G.R.; Calvey, T.N.; Muir, K.T. The pharmacokinetics of pyridostigmine and 3-hydroxy-N-methylpyridinium in the rat: Dose-dependent effects after portal vein administration. Br. J. Pharmacol. 55: 335-341. 1975.
17. 14C-pyridogtigmine in the rat. Br. J. Pharmacol. Chemother. 26: 393-402. 1966.
18. Meyer, H.G.; Lukey, B.J.; Gepp, R.T.; Corpuz, R.P.; Lieske, C.N. A radioimmunoassay for pyridostigmine. J. Pharmacol. Exp. Ther. 247. 132-438. 1988.
19. Miller, R.L.; Verma, P. Radioimmunoassay of pyridostigmine in plasma and tissues. Pharmacol. Res. 21: 359-368. 1989.
20. Baker, P.R.; Calvey, T.N.; Chan, K.; Macnee, C.M.; Taylor, K. Plasma clearance of neostigmine and pyridostigmine in the dog. Br J Pharmacol. 63: 509-512.1978.
21. Hennis, P.J.; Cronnelly, R.; Sharma, M.; Fisher, D.M.; Miller, R.D. Metabolites of neostigmine and pyridostigmine do not contribute to antagonism of neuromuscular blockade in the dog. Anesthesiology. 61: 534-539. 1984.
22. Taylor, T.; Hawkins, D.R.; Forrest, T.J.; Chung, H. Pharmacokinetics of pyridostigmine in dogs. J Pharm Sci. 80: 353-356. 1991.
23. Somani, S.M.; Roberts, J.B.; Wilson, A. Pyridostigmine metabolism in man. Clin Pharmacol Ther. 13: 393-399. 1972.
24. Williams, N.E.; Calvey, T.N.; Chen, K. Plasma concentration of pyridostigmine during the antagonism of neuromuscular block. Br J Anaesth. 55: 27-31.1983.
25. Davison, S.C.; Hyman, N.M.: Dehghan, A.; Chan, K. The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry. 44: 1141-1145. 1981.
26. Abu-Qare, A.W.; Abon-Donia, M.B. Determination of depleted uranium, pyridostigmine bromide and its metabolite in plasma and urine following combined administration in rats. J Pharm Biomed Anal. 26: 281-289. 2001.
27. Chan, K.; Williams, N.E.; Baty, J.D.; Calvey, T.N. A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J. Chromatogr. 120: 349-358. 1976.
28. Nowell, P.T.; Scott, C.A.; Wilson, A. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis. Br J Pharmacol 18: 617. 1962.
29. Hardell, L.I.; Lindstrorn, B.; Lonnerholm, G.; Osterman, P.O. Pyridostigmine in human breast milk. Br. J. Clin. Pharmacol. 14: 565-567. 1982.
30. Barber, H.E.; Calvey, T.N.; Muir, K.T. The relationship between the pharmacokinetics, cholinesterase inhibition and facilitation of twitch tension of the quaternary ammonium anticholinesterase drugs, neostigmine, pyridostigtmine, edrophonium and 3-hydroxyphenyltrimethylammonium Br J Pharmacol. 66: 525-530. 1979.
31. Husain M.A.; Roberts, J.B.; Thomas, B.H.; Wilson, A. The excretion and metabolism of oral 14C-pyridostigmine in the rat. Br J Pharmacol. 34: 445-50. 1968.
32. Pohlmann, J.L.; Cohan, S.L. Simplefield detection of quaternary ammonium compounds by gas chromatography. J Chromatogr. 131: 297-301. 1977.
33. Aquilonius, S.M.; Eckernas, S.A., Hartvig, P.; Lindstrom, B.; Osterman, P.O. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol. 18: 423-428. 1980.
34. Whelpton, R. Analysis of plasma physostigmine concentrations by liquid chromatography. J Chromatogr. 272: 216-220. 1983.
35. Whelpton, R.; Moore, T. Senitive liquid chrmatographic method for physostigmne in biological fluids using dual-electrode electrochemical detection. J Chromotogr. 341: 361-371. 1985.
36. Brodie, R.R.; Chasseaud, L.F.; Robbins, A.D. Determination of physostigmine in plasma by high-performance liquid chromatography, J Chromatogr. 415: 423-431. 1937.
37. Elsayed, N.M.; Ryabik, J.R.; Ferraris, S.; Wheeler, C.R.; Korte, D. W. Jr. Determination of physostigmine in plasma by high-peformance liquid chromatography and fluorescence detection. Anal Biochem. 177: 207-211. 1989.
38. Matsunaga, H.; Suehiro, T.; Saita, T.; Nakano, Y.; Mori, M.; Takata, K.; Oda, K. High-performance liquid chromatographic determination of pyridostigmine in plasma. J Chromatogr. 422: 353-355. 1987.
39. Yturralde, O.; Lee, R.Y; Benet, L.Z.; Flechenstein, L.; Lin, E.T.L. Ion-paired liquid chromatographic method for the analysis of pyridostigmine in plasma. J. Liq. Chromatogr. 10: 2231-2246. 1987.
40. De Ruyter, M.G.; Cronnelly, R. Reversed-phase, ion-pair liquid chromatography of quaternary ammonium compounds: determination of pyridostigmine, neostigmine and edrophionium in biological fluids. J Chromatogr. 183: 193-201. 1930.
41. Coper, H.; Deyhle, G.; Dross, K. Studies on the absorption of pyridostigmine: the applicaticn of a spectrophotometric method for the determination of pyridostigmine in plasma. Z Klin Chem Klin Biochem. 12: 273-275. 1974.
42. van der Maeden, F.P.; van Rens, P.T.; Buytenhuys, F.A.; Buurman, E. Quantitative analysis of dtubucurarine chloride in curare by column liquid chromatography. J Chromatogr. 142. 715-723. 1977.
43. Malcolm, S.L.; Madigan, M.J.; Tayler, N.L. Thermospray mass spectrometer as a quantitative specific, sensitive, detector for liquid chromatography. Its application to the analysis of pyridostigmine in human plasma. J Pharm Biomed Anal. 8, 771-776. 1990.
44. Noedham, S.R.; Ye, B.; Smith. J.R.; Korte, W.D. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of pyridostigmine bromide Technol Biomed Life Sci. 796: 347-354. 2003.
45. Davison, S.C.; Hyman, N.; Prentis, R.A.; Dehghan, A.; Chan, K. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man. methods Find Exp Clin Pharmacol. 2: 77-82. 1980.
46. Cohan. S.L.; Pohlmann. J.L.; Mikszewski, J.; O'Doherty, D.S. The pharmacokinetics of pyridostigmine. Neurology. 26: 536-539. 1976.
47. Sorensen, P.S.; Flachs, H.; Friis, M.L.; Hvidberg, E.F.; Paulson, O.B. Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology. 34: 1020-1024. 1984.
48. Altria K.D.; Bestford, J. Main component assay of pharmaceuticals by capillary electrophoresis: considerations regarding precision, accuracy, and linearity data. J Cap Elec. 3: 13-23. 1996.
49. Hadley, M.; Gilges. M., Senior, J.; Shah, A.; Camilleri, P. Capilliary electrophoresis in the pharmaceutical industry: applications in discovery and ohemical development. J Chromatogr. B. 745: 177-188. 2000.
50. Havel, J.; Patocka, J.; Bocaz, G. Determination of physostigmine and pyridostigmine in pharmaceutical formulations by capillary electrophoresis. J Cap. Elec Microchip Tech. 7: 107-112. 2002.
51. Michaelis, H.C. Determination of pyridostigmine plasma concentrations by high-performance liquid chromatography. J Chromatogr. 534: 291-294. 1990.
52. Abu-Qare, A.W.; Abou-Donia M.B. Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine. J Chromatogr B. 754: 503-509. 2001.
53. Cherstniakova, S.; Garcia, G.; Strong, J.; Helbling, N.; Bi, D.; Roy, M.; Cantilena, L.R. Simultaneous determination of N, N-diethyl-M-toluamide and permethrin by GC-MS and pyridostigmine bromide by HPLC in human plasma. Application to pharmacokinetic studies. Clin. Pharmacol, Ther. 73: 27. 2003.